METTL17

Across TCGA pan-cancer cohorts, METTL17 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated METTL17 data layer compared with 18 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher METTL17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL17 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where METTL17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.315	0.612	.002	16	view →
LUAD	OS	Median	All	0.636	0.945	.011	12	view →
LSCC	DFS	Tertile	II,III,IV	0.826	0.485	.007	10	view →
GBM	DFS	Quartile	All	0.616	0.228	.010	9	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	8	view →
UCEC	DFS	Median	III,IV	0.889	0.460	.044	4	view →
HNSC	OS	Quartile	II,III,IV	0.670	0.894	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

METTL17–PDAC (DFS)

Open the PDAC breakdown →